Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesMedical treatment of vestibular disorders
Expert Opinion in Pharmacotherapy, 06/19/09
Brandt T et al. - In vestibular neuritis, recovery of the peripheral vestibular function can be improved by oral corticosteroids; in Meniere's disease, there is first evidence that high-dose, long-term administration of betahistine reduces attack frequency; carbamazepine or oxcarbamazepine is the treatment of first choice in vestibular paroxysmia, a disorder mainly caused by neurovascular cross-compression; the potassium channel blocker aminopyridine provides a new therapeutic principle for treatment of downbeat nystagmus, upbeat nystagmus, and episodic ataxia type 2.
Related Articles
Bilateral Vestibulopathy: Clinical, Diagnostic, and Genetic Considerations
Seminars in Neurology, 11/02/09
Relevance Score: 67%
Vertigo Presentations in the Emergency Department
Seminars in Neurology, 10/28/09
Relevance Score: 67%
Anatomical and Physiological Considerations in Vestibular Dysfunction and Compensation
Seminars in Hearing, 10/26/09
Relevance Score: 67%
Vestibular Neuritis
Seminars in Neurology, 10/30/09
Relevance Score: 66%
Imbalance and Vertigo: The Aging Human Vestibular Periphery
Seminars in Neurology, 10/28/09
Relevance Score: 66%
Today in Dosing...keeping you current
Receive free subspecialty "5-minute updates" via email
High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial
BMC Infectious Diseases, 12/03/09
Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: A double- blind, randomized, multicentre, placebo-controlled trial
Amyotrophic Lateral Sclerosis, 12/03/09
Ustekinumab (Stelara): First-in-class human monoclonal antibody approved for treatment of moderate-to-severe plaque psoriasis
Formulary , 12/02/09
Today in Other Drugs...keeping you current
Receive free subspecialty "5-minute updates" via email
Clinical applications for topical 5-fluorouracil in the treatment of dermatological disorders
Journal of Dermatological Treatment , 12/04/09
Non-psoriatic dermatologic uses of monoclonal antibody therapy
Journal of Dermatological Treatment , 12/04/09
Does Simvastatin Cause More Myotoxicity Compared with Other Statins
Annals of Pharmacotherapy, 12/03/09
Sponsor
Article Search
Sponsor